<DOC>
	<DOCNO>NCT00400946</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving give one drug ( combination chemotherapy ) may kill cancer cell . It yet know whether pegasparaginase effective asparaginase give together combination chemotherapy treat acute lymphoblastic leukemia . PURPOSE : This randomized phase III trial study pegasparaginase see well work compare asparaginase give together combination chemotherapy treat young patient newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Treatment Acute Lymphoblastic Leukemia Children</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare relative toxicity pegasparaginase v E. coli asparaginase administer combination chemotherapy child newly diagnose acute lymphoblastic leukemia ( ALL ) . Secondary - Compare relative efficacy regimens patient . - Determine prognostic significance asparaginase antibody formation . - Correlate trough enzyme level outcome ( toxicity relapse ) . - Compare quality life patient treat pegasparaginase v E. coli asparaginase . - Compare trough serum asparaginase enzyme level , asparagine level , anti-asparaginase antibody level patient treat regimen . - Determine rate infection ( episode bacteremia disseminate fungal infection ) remission induction phase combination chemotherapy patient . - Determine prognostic significance response remission induction chemotherapy measure morphology minimal residual disease ( MRD ) measure . - Determine outcome patient base MRD status 28 day multiagent chemotherapy intensifies treatment B-lineage patient MRD level great 0.001 end remission induction therapy . - Determine outcome patient base MRD status 14 day multiagent chemotherapy various time point treatment ( every 18 week achieve complete remission completion chemotherapy ) . - Compare outcome ( base bone marrow morphology 14 day multiagent chemotherapy ) patient M2/M3 status time point v M1 status hypoplastic marrow . - Determine efficacy CNS-related toxicity CNS-directed treatment patient . - Determine efficacy CNS-related toxicity ( acute long-term ) high-risk ( HR ) regimen subset HR patient treat intensive intrathecal ( IT ) chemotherapy remainder treat cranial radiation therapy ( concurrent IT chemotherapy ) . - Determine efficacy CNS-related toxicity ( acute long-term ) intensive IT therapy standard-risk patient . - Correlate dietary antioxidant micronutrient intake ( include ascorbic acid , vitamin E , vitamin A , beta carotene , total carotenoid ) rate infection ( episode bacteremia disseminate fungal infection ) remission induction therapy consolidation IA phase . - Correlate dietary calcium intake risk development fracture continuation phase therapy . OUTLINE : This randomize , multicenter , open-label study . Patients stratify accord disease risk ( standard-risk [ SR ] v high-risk [ HR ] vs high risk [ VHR ] ) . - Steroid prophase* : Patients receive intrathecal ( IT ) cytarabine day 1 methylprednisolone IV every 8 hour day 1-3 . Patients proceed remission induction therapy . Patients CNS leukemia ( CNS-2 , CNS-3 , traumatic lumbar puncture [ LP ] blast ) initial LP receive additional IT cytarabine twice weekly begin day 4-6 continue cerebrospinal fluid ( CSF ) clear , follow 2 additional dos . Patients cranial nerve palsy leukemia blast CSF leukemic eye infiltrates also receive additional IT cytarabine . NOTE : *Patients receive steroid within past 7 day receive steroid prophase treatment ; instead proceed directly remission induction therapy accord risk group . - Remission induction therapy ( SR patient ) : Patients receive oral prednisone prednisolone 2-3 time daily OR methylprednisolone IV every 8 hour day 4-32 ; vincristine IV day 4 , 11 , 18 , 25 ; doxorubicin hydrochloride ( DOX ) IV 15 minute day 4 5 ; methotrexate ( MTX ) IV day 6 ; pegasparaginase IV 1 hour day 7 ; triple intrathecal therapy ( TIT ) comprise methotrexate , cytarabine , hydrocortisone day 18 ; IT MTX day 32 . NOTE : Patients receive steroid prophase treatment also receive IT cytarabine day 4 . - Remission induction therapy ( HR VHR patient ) : Patients receive prednisone/prednisolone OR methylprednisolone ; vincristine ; DOX ; MTX IV ; pegasparaginase ; TIT ; IT MTX SR group . Patients also receive dexrazoxane hydrochloride IV 15 minute precede DOX infusion day 4 5 . NOTE : Patients receive steroid prophase treatment also receive IT cytarabine day 4 . Patients complete remission ( CR ) day 32 proceed consolidation I . Patients CR day 32 receive vincristine IV weekly CR achieve . Patients persistent marrow ( great 5 % leukemic blast ) achieve CR day 53 remove study . Patients CSF blast cytospin least 5 WBC/high-power field ( hpf ) CSF ( CNS-3 ) remission induction therapy remove study . Patients CSF blast less 5 WBC/hpf CSF ( CNS-2 ) receive 1 course systemic chemotherapy comprise vincristine IV week 4 week ; dexrazoxane hydrochloride IV 15 minute follow DOX IV 15 minute day 2 day ; oral mercaptopurine day 2 week . Patients persistent CNS blast day 53 remove study . Patients CNS blast day 53 proceed consolidation I . - Consolidation I ( SR patient ) : Patients receive vincristine IV IT MTX day 1 oral mercaptopurine daily day 1-14 . Patients also receive high-dose MTX ( HDM ) IV continuously 24 hour day 1 leucovorin calcium IV every 6 hour begin 36 hour start HDM infusion continue MTX level undetectable . Patients proceed CNS therapy day 21 . - Consolidation I ( HR patient ) : Patients receive vincristine , IT MTX , mercaptopurine SR group . Patients also receive dexrazoxane hydrochloride IV 15 minute follow DOX IV 15 minute day 1 HDM leucovorin calcium support SR group begin 8-24 hour completion DOX infusion . Patients proceed CNS therapy day 21 . - Consolidation I ( VHR patient ) : Patients receive consolidation therapy 3 stage . - Stage IA : Patients receive vincristine , IT MTX , mercaptopurine SR group . Patients also receive dexrazoxane hydrochloride , DOX , HDM , leucovorin calcium HR group . - Stage IB : Patients receive cyclophosphamide IV 1 hour IT MTX day 22 ; oral mercaptopurine daily day 22-35 ; cytarabine IV day 23-26 30-33 . - Stage IC : Patients receive high-dose cytarabine IV 3 hour every 12 hour day 43 44 ; etoposide IV 1 hour day 45-47 ; oral dexamethasone twice daily day 43-47 . Patients also receive E. coli asparaginase* intramuscularly ( IM ) weekly begin day 48 continue 30 week OR pegasparaginase* IV 1 hour every 2 week begin day 48 continue 30 week . Patients proceed CNS therapy day 49 . NOTE : *Patients either randomized receive E. coli asparaginase pegasparaginase OR assign receive E. coli asparaginase . Patients continue receive E. coli asparaginase pegasparaginase CNS therapy consolidation II therapy . - CNS therapy ( SR patient ) : Patients receive vincristine IV day 1 ; oral mercaptopurine daily day 1-14 ; oral dexamethasone twice daily day 1-5 ; TIT twice weekly 2 week . Patients also receive E. coli asparaginase* OR pegasparaginase* begin day 1 continue 30 week . Patients proceed consolidation II day 21 . NOTE : *Patients either randomized receive E. coli asparaginase pegasparaginase OR assign receive E. coli asparaginase . Patients continue receive E. coli asparaginase pegasparaginase consolidation II therapy . - CNS therapy ( HR VHR patient ) : Patients receive vincristine , mercaptopurine , dexamethasone , TIT SR group . Patients also receive dexrazoxane hydrochloride IV 15 minute follow DOX IV 15 minute day 1 . HR patient also receive E. coli asparaginase OR pegasparaginase begin day 1 continue 30 week . VHR patient continue receive E. coli asparaginase OR pegasparaginase per consolidation I treatment . Patients proceed consolidation II day 21 . Patients WBC &gt; 100,000/mm³ , T-cell disease , and/or CNS-3 diagnosis CNS-2 end remission induction therapy also undergo cranial radiation therapy daily 8 10 day . - Consolidation II ( SR patient ) : Patients receive vincristine IV day 1 ; oral dexamethasone twice daily day 1-5 ; oral mercaptopurine daily day 1-14 . Treatment repeat every 21 day E. coli asparaginase pegasparaginase complete . Patients also receive MTX IV IM 1 day E. coli asparaginase pegasparaginase dose TIT every 9 week 6 dos every 18 week thereafter . - Consolidation II ( HR VHR patient ) : Patients receive vincristine , dexamethasone , mercaptopurine SR group . Patients also receive dexrazoxane hydrochloride IV 15 minute follow DOX IV 15 minute day 1 . Treatment repeat every 21 day E. coli asparaginase pegasparaginase complete . Patients also receive MTX IV IM SR group TIT every 9 week 6 dos every 18 week thereafter OR TIT every 18 week . - Continuation therapy : After completion consolidation therapy , patient receive vincristine IV day 1 ; oral dexamethasone twice daily day 1-5 ; oral mercaptopurine daily day 1-14 ; MTX IV IM day 1 , 8 , 15 . Treatment repeat every 21 day 2 year achieve CR . Patients continue receive TIT consolidation II 2 year achieve CR . Patients complete dietary questionnaire time diagnosis , day 32 , 12 month diagnosis . Quality life assess periodically . After completion study therapy , patient follow periodically 3 year annually thereafter . PROJECTED ACCRUAL : A total 544 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute lymphoblastic leukemia ( ALL ) No known mature Bcell ALL , define presence following : Surface immunoglobulin L3 morphology ( 8 ; 14 ) ( q24 ; q32 ) ( 8 ; 22 ) ( 2 ; 8 ) Tcell surface marker ( 8 ; 14 ) ( q24 ; q11 ) allow Meets criterion 1 follow risk group : Standardrisk ( SR ) disease , define follow criterion : 1 9 year age Highest pretreatment WBC &lt; 50,000/mm³ No evidence CNS leukemia , define follow : Diagnostic lumbar puncture without cerebrospinal fluid ( CSF ) blast cell cytospin ( CNS1 ) OR &lt; 5 WBC/highpower field ( hpf ) CSF blast cell cytospin ( CNS2 ) CNS1 CSF day 18 32 study treatment Absence cranial nerve palsy diagnosis Absence Tcell marker lymphoblasts Absence ( 9 ; 22 ) , mixedlineage leukemia ( MLL ) gene translocation , hypodiploidy &lt; 45 chromosome karyotype fluorescent situ hybridization ( FISH ) Minimal residual disease ( MRD ) level &lt; 0.001 end study remission induction therapy ( day 32 ) OR endofinduction MRD status determine Highrisk ( HR ) disease , define follow criterion : 10 17 year age Highest pretreatment WBC ≥ 50,000/mm³ Evidence CNS leukemia , define follow : Diagnostic lumbar puncture ≥ 5 WBC/hpf blast cell cytospin ( CNS3 ) CNS2 CSF day 18 32 study treatment CNS3 CSF day 18 study treatment Presence cranial nerve palsy diagnosis Predominance Tcell marker lymphoblasts Presence ( 9 ; 22 ) An allogeneic stem cell donor seek transplantation These patient receive CNS therapy study treatment Blineage MRD level &lt; 0.001 end study remission induction therapy ( day 32 ) OR endofinduction MRD status determine Very highrisk ( VHR ) disease , define follow criterion : Presence MLL gene translocation ( i.e. , [ 4 ; 11 ] ) karyotype , FISH , molecular analysis Presence hypodiploidy &lt; 45 chromosome karyotype FISH analysis MRD level ≥ 0.001 end study remission induction therapy ( day 32 ) No secondary ALL PATIENT CHARACTERISTICS : No known HIV positivity Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior therapy except steroid ≤ 1 week duration and/or emergent radiation therapy mediastinum Patients treat steroid within past 7 day receive steroid prophase study treatment</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
</DOC>